<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3976">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01306253</url>
  </required_header>
  <id_info>
    <org_study_id>INF-V-A003</org_study_id>
    <nct_id>NCT01306253</nct_id>
  </id_info>
  <brief_title>A Re-licensing Study to Assess the Efficacy of Inflexal V Formulated With WHO Recommended 2009/2010 Influenza Virus Strains for the Northern Hemisphere</brief_title>
  <official_title>Open, Non-randomized Trial to Assess the Immunogenicity and Safety of the 2009/2010-season Influenza Vaccine in Elderly and Young Subjects According to European Medicines Agency (EMEA) Regulations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Crucell Holland BV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Crucell Holland BV</source>
  <oversight_info>
    <authority>Switzerland: Swissmedic</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to assess whether the Northern Hemisphere 2009/2010 season influenza vaccine
      Inflexal V fulfills the EMEA requirements for re-registration of influenza vaccines.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Seroconversion</measure>
    <time_frame>Day 22 ± 2 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Seroconversion rate was defined as the number of subjects with ≥4-fold increase in haemagglutination inhibition (HI) antibody titer and with a titer of ≥1:40</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Seroprotection</measure>
    <time_frame>Day 22 ± 2 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Seroprotection rate, defined as the number of subjects with HI antibody titer ≥1:40</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fold Increase in Geometric Mean Titer (GMT)</measure>
    <time_frame>Day 22/Day 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>GMT-fold increase - calculated as the GMT on Day 22 divided by the baseline GMT value</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety: Numbers of Subjects Reporting Solicited Local Adverse Events</measure>
    <time_frame>Days 1 to 4 inclusive, and Day 22</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety assessments are made by the investigator at baseline and on Day 22 as well as by the subjects themselves (in a Subject Diary) for the 4-day period immediately following vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Numbers of Subjects Reporting Solicited Systemic Adverse Events</measure>
    <time_frame>Days 1 to 4 inclusive, and Day 22</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety assessments are made by the investigator at baseline and on Day 22 as well as by the subjects themselves (in a Subject Diary) for the 4-day period immediately following vaccination</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">114</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Elderly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Elderly subjects aged over 60 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adults</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adults from 18 to 60 years old inclusive</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Inflexal V</intervention_name>
    <description>Inflexal V influenza vaccine, formulated for the WHO requirements of the 2009-2010 season, containing per 0.5 mL dose:
15 µg hemagglutinin (HA) antigen of A/Brisbane/59/2007 (H1N1)-like virus
15 µg HA antigen of A/Brisbane/10/2007 (H3N2)-like virus
15 µg HA antigen of B/Brisbane/60/2008-like virus
Dose: intramuscular administration (M. deltoides) of a single dose of 0.5 mL on Day 1</description>
    <arm_group_label>Elderly</arm_group_label>
    <arm_group_label>Adults</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy female and male adults

          -  Aged ≥18 to ≤60 years or &gt;60 years on Day 1

          -  Written informed consent

        Exclusion criteria:

          -  Acute exacerbation of bronchopulmonary infection (cough, sputum, lung findings) or
             other acute disease

          -  Acute febrile illness (≥38.0 °C)

          -  Prior vaccination with an influenza vaccine in the past 330 days

          -  Known hypersensitivity to any vaccine component

          -  Previous history of a serious adverse reaction to influenza vaccine

          -  History of egg protein allergy or severe atopy

          -  Known blood coagulation disorder

          -  Chronic (longer than 14 days) administration of immunosuppressants or other
             immune-modifying drugs within 6 months before the first dose of study vaccine, incl.
             oral corticosteroids in dosages of ≥0.5 mg/kg/d prednisolone or equivalent (inhaled
             or topical steroids are allowed)

          -  Known immunodeficiency (incl. leukemia, cancer, HIV seropositivity)

          -  Investigational medicinal product received in the past 3 months (90 days)

          -  Treatment with immunoglobulins or blood transfusion(s) received in the past 3 months
             (90 days)

          -  Pregnancy or lactation

          -  Participation in another clinical trial

          -  Employee at the investigational site, or relative or spouse of the investigator

          -  Suspected non-compliance
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Seiberling, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Covance Clinical Research Unit AG</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Unit AG</name>
      <address>
        <city>Allschwil</city>
        <zip>4123</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 29, 2013</lastchanged_date>
  <firstreceived_date>February 28, 2011</firstreceived_date>
  <firstreceived_results_date>December 14, 2011</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Influenza</keyword>
  <keyword>Virus</keyword>
  <keyword>Vaccination</keyword>
  <keyword>Immunisation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited at one center in Switzerland First subject first visit (FSFV): 05-Jun-2009 Last subject last visit (LSLV): 30-Jun-2009</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Adults</title>
          <description>Adults from 18 to 60 years old inclusive</description>
        </group>
        <group group_id="P2">
          <title>Elderly</title>
          <description>Elderly subjects aged over 60 years</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
                <participants group_id="P2" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Adults</title>
          <description>Adults from 18 to 60 years old inclusive</description>
        </group>
        <group group_id="B2">
          <title>Elderly</title>
          <description>Elderly subjects aged over 60 years</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="57"/>
                <measurement group_id="B2" value="57"/>
                <measurement group_id="B3" value="114"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="42.3" spread="12.3"/>
                <measurement group_id="B2" value="68.5" spread="5.8"/>
                <measurement group_id="B3" value="55.4" spread="16.3"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="31"/>
                <measurement group_id="B2" value="30"/>
                <measurement group_id="B3" value="61"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="26"/>
                <measurement group_id="B2" value="27"/>
                <measurement group_id="B3" value="53"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Seroconversion</title>
        <description>Seroconversion rate was defined as the number of subjects with ≥4-fold increase in haemagglutination inhibition (HI) antibody titer and with a titer of ≥1:40</description>
        <time_frame>Day 22 ± 2 days</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intention-to-treat (ITT) and According-to-protocol (ATP) populations excludes one subject per group lost to follow up</population>
        <group_list>
          <group group_id="O1">
            <title>Adults</title>
            <description>Adults from 18 to 60 years old inclusive</description>
          </group>
          <group group_id="O2">
            <title>Elderly</title>
            <description>Elderly subjects aged over 60 years</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="56"/>
                  <measurement group_id="O2" value="56"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Seroconversion</title>
            <description>Seroconversion rate was defined as the number of subjects with ≥4-fold increase in haemagglutination inhibition (HI) antibody titer and with a titer of ≥1:40</description>
            <units>Number of subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>A/Brisbane/59/2007</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="29"/>
                  <measurement group_id="O2" value="32"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/Brisbane/10/2007</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="37"/>
                  <measurement group_id="O2" value="35"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>B/Brisbane/60/2008</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="34"/>
                  <measurement group_id="O2" value="33"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety: Numbers of Subjects Reporting Solicited Local Adverse Events</title>
        <description>Safety assessments are made by the investigator at baseline and on Day 22 as well as by the subjects themselves (in a Subject Diary) for the 4-day period immediately following vaccination</description>
        <time_frame>Days 1 to 4 inclusive, and Day 22</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Safety population includes all subjects who received study vaccine</population>
        <group_list>
          <group group_id="O1">
            <title>Adults</title>
            <description>Adults from 18 to 60 years old inclusive</description>
          </group>
          <group group_id="O2">
            <title>Elderly</title>
            <description>Elderly subjects aged over 60 years</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="57"/>
                  <measurement group_id="O2" value="57"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Safety: Numbers of Subjects Reporting Solicited Local Adverse Events</title>
            <description>Safety assessments are made by the investigator at baseline and on Day 22 as well as by the subjects themselves (in a Subject Diary) for the 4-day period immediately following vaccination</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Ecchymosis</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Erythema</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5"/>
                  <measurement group_id="O2" value="3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Induration</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Pain</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Seroprotection</title>
        <description>Seroprotection rate, defined as the number of subjects with HI antibody titer ≥1:40</description>
        <time_frame>Day 22 ± 2 days</time_frame>
        <safety_issue>No</safety_issue>
        <population>ITT/ATP</population>
        <group_list>
          <group group_id="O1">
            <title>Adults</title>
            <description>Adults from 18 to 60 years old inclusive</description>
          </group>
          <group group_id="O2">
            <title>Elderly</title>
            <description>Elderly subjects aged over 60 years</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="56"/>
                  <measurement group_id="O2" value="56"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Seroprotection</title>
            <description>Seroprotection rate, defined as the number of subjects with HI antibody titer ≥1:40</description>
            <units>Number of subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>A/Brisbane/59/2007</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="47"/>
                  <measurement group_id="O2" value="47"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/Brisbane/10/2007</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="49"/>
                  <measurement group_id="O2" value="51"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>B/Brisbane/60/2008</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="51"/>
                  <measurement group_id="O2" value="46"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Fold Increase in Geometric Mean Titer (GMT)</title>
        <description>GMT-fold increase - calculated as the GMT on Day 22 divided by the baseline GMT value</description>
        <time_frame>Day 22/Day 1</time_frame>
        <safety_issue>No</safety_issue>
        <population>ITT/ATP</population>
        <group_list>
          <group group_id="O1">
            <title>Adults</title>
            <description>Adults from 18 to 60 years old inclusive</description>
          </group>
          <group group_id="O2">
            <title>Elderly</title>
            <description>Elderly subjects aged over 60 years</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="56"/>
                  <measurement group_id="O2" value="56"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Fold Increase in Geometric Mean Titer (GMT)</title>
            <description>GMT-fold increase - calculated as the GMT on Day 22 divided by the baseline GMT value</description>
            <units>Fold (ratio)</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>A/Brisbane/59/2007</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9.60"/>
                  <measurement group_id="O2" value="5.93"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>A/Brisbane/10/2007</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="9.25"/>
                  <measurement group_id="O2" value="8.30"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>B/Brisbane/60/2008</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="7.91"/>
                  <measurement group_id="O2" value="6.93"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Numbers of Subjects Reporting Solicited Systemic Adverse Events</title>
        <description>Safety assessments are made by the investigator at baseline and on Day 22 as well as by the subjects themselves (in a Subject Diary) for the 4-day period immediately following vaccination</description>
        <time_frame>Days 1 to 4 inclusive, and Day 22</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Safety population</population>
        <group_list>
          <group group_id="O1">
            <title>Adults</title>
            <description>Adults from 18 to 60 years old inclusive</description>
          </group>
          <group group_id="O2">
            <title>Elderly</title>
            <description>Elderly subjects aged over 60 years</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="57"/>
                  <measurement group_id="O2" value="57"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Numbers of Subjects Reporting Solicited Systemic Adverse Events</title>
            <description>Safety assessments are made by the investigator at baseline and on Day 22 as well as by the subjects themselves (in a Subject Diary) for the 4-day period immediately following vaccination</description>
            <units>Subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Malaise</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Shivering</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Fever</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0"/>
                  <measurement group_id="O2" value="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Safety assessments were made by the investigator at baseline and on Day 22 (± 2 days), and by subjects themselves (Subject Diary) for the 4-day period post-vaccination. SAE surveillance extended to 6 months post-vaccination.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Adults</title>
          <description>Adults from 18 to 60 years old inclusive</description>
        </group>
        <group group_id="E2">
          <title>Elderly</title>
          <description>Elderly subjects aged over 60 years</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="57"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="57"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Induration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="57"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="57"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="57"/>
              </event>
              <event>
                <sub_title>Monoparesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="57"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="57"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The investigator to submit all manuscripts/abstracts to the sponsor for review at least 6 weeks before submission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Affairs Director</name_or_title>
      <organization>Crucell Switzerland AG</organization>
      <phone>+41(0)319806111</phone>
      <email>info@crucell.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
